media – Page 140 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

CEO of radiotherapy giant resigns

Recently, Elekta (EKTA-B.ST) announced that its President and CEO, Gustaf Salford, and board of directors have unanimously decided to resign on March 6th. The board of directors of Yikeda is conducting international recruitment for the position of new CEO. During this period, the board has appointed Jonas Bolander, Executive Vice President, General Counsel, and Group Functional Head with 23 years of experience at Medda, as Acting President and CEO. 01. Net profit decreased by 30% For the nine months ending January 31, 2025, Elekta achieved revenue of 12.86 billion Swedish kronor and a net profit of 621 million Swedish kronor. Compared to the same period last year, net profit decreased by 30% and revenue decreased by 2%. In the latest Medical Technology Top 100 Report, it ranks 56th in annual revenue. Dr. Laurent (Larry) Leksell, Chairman of the Board, stated, “Although Elekta’s mid-term performance in the third quarter did not ...
- Source: drugdu
- 281
- March 4, 2025
Seven new rare disease drugs have been given priority review, from companies such as Johnson&Johnson, Rongchang Biotech, and Hansen Pharmaceuticals

Every year’s Rare Disease Day is an important moment for us to pay attention to these ‘minority groups’. For rare disease patients, the development and approval of new drugs mean hope for life. In recent months, the China National Medical Products Administration’s Center for Drug Evaluation (CDE) has prioritized the evaluation of multiple rare disease drugs, including symptomatic giant cell tumors of the tendon sheath, myasthenia gravis, giant cell arteritis, idiopathic pulmonary fibrosis, and other indications. These drugs are expected to accelerate approval and bring new treatment options to patients. This article will review the research and development progress of 7 new drugs based on publicly available information, hoping that they will be launched soon and light up the future for rare disease patients. According to the official website of CDE, since September 2024, CDE has added a “rare disease drug” label to new drugs included in priority review. This ...
- Source: drugdu
- 861
- March 4, 2025
Hengrui steps down as the ‘top pharmaceutical expert’, and BeiGene ascends to the top for the first time! How can Hengrui break through?

Recently, Hengrui Pharmaceutical has lost its position as the “top pharmaceutical company”. On February 21st, the A-share pharmaceutical sector ushered in a historic turning point – at the closing price, BeiGene surpassed Hengrui Pharmaceutical’s 308 billion yuan market value with a market value of 310.7 billion yuan, and for the first time topped the A-share pharmaceutical company market value list with a slight advantage of 2.7 billion yuan, overturning Hengrui Pharmaceutical’s long-standing position as the “top pharmaceutical company”. BeiGene’s transcendence sends a signal. For a long time in the past, Hengrui Pharmaceutical was undoubtedly the leader in the pharmaceutical industry. With its “imitation+innovation” model, Hengrui has been leading the entire industry, and its multiple core products once occupied half of the domestic pharmaceutical market. As early as 2021, the stock price of Hengrui Pharmaceutical continued to rise after a continuous surge, reaching a peak of 96.7 yuan per share, with ...
- Source: drugdu
- 528
- March 4, 2025
Chengdu Pioneer disclosed its shareholder reduction plan; Amycritin Injection Approved for Clinical Use in China | Medical Early Reference

NO.1 Support qualified traditional Chinese medicine and other biopharmaceutical companies to issue and list on the Shanghai and Shenzhen stock exchanges The China Securities Regulatory Commission has issued a letter in response to Proposal No. 4171 (Finance, Taxation, and Finance 261) of the Second Session of the 14th National Committee of the Chinese People’s Political Consultative Conference. Among them, it is mentioned that actively supporting qualified biopharmaceutical companies, including traditional Chinese medicine, to issue and list on the Shanghai and Shenzhen stock exchanges, focusing on expanding direct financing channels for biopharmaceutical companies, and fully leveraging the supportive role of the capital market in the development of the biopharmaceutical industry. Commentary: The China Securities Regulatory Commission supports the listing of traditional Chinese medicine and other biopharmaceutical companies, expanding direct financing channels. This move will help promote innovative development in the biopharmaceutical industry, enhance the support of the capital market for the ...
- Source: drugdu
- 245
- March 4, 2025
164 measles cases have been reported in the United States

Robert Kennedy, Secretary of the U.S. Department of Health and Human Services, said he was aware of the serious impact of the current measles outbreak in Texas, and ending the measles outbreak was the top priority for him and his team. The U.S. Department of Health and Human Services will provide 2,000 doses of measles, mumps and rubella vaccines to Texas through its immunization program. According to data from the U.S. Centers for Disease Control and Prevention (CDC) on February 27, 164 measles cases have been reported in the United States, an increase of nearly 80% from the 93 cases reported a week ago. Of these cases, about 95% were from unvaccinated people, and another 3% were from people who had only received one dose and had not completed all immunizations. https://finance.eastmoney.com/a/202503013333801648.html
- Source: drugdu
- 200
- March 4, 2025
Kangleweishi’s nine-valent HPV vaccine research and development has made significant progress

On the evening of February 28, Kangleweishi issued an announcement stating that on the same day, the independent data monitoring committee (IDMC) of the domestic phase III protective efficacy clinical trial of the company’s independently developed recombinant nine-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (Escherichia coli) (female indication) has completed the first analysis unblinding, primary efficacy indicators and safety evaluation, and the company has received the IDMC’s recommendation letter based on the first analysis results. The company stated that the independent data monitoring committee (IDMC) confirmed that the efficacy results met the first analysis statistical criteria preset in the protocol. The first analysis results of the company’s nine-valent HPV vaccine (female indication) domestic phase III protective efficacy clinical trial were in line with expectations, marking a major progress in the clinical research of the nine-valent HPV vaccine. The company said the development is not expected to have a material impact on its ...
- Source: drugdu
- 226
- March 4, 2025
Rabies vaccine market share continues to fall, Chengda Bio’s performance shrinks and it is difficult to break through

Rabies vaccine leader Chengda Bio (688739.SH) recently disclosed its performance report. In 2024, the company achieved operating income of 1.676 billion yuan, a year-on-year decline of 4.22%; and achieved a net profit attributable to the parent of 334 million yuan, a year-on-year decrease of 28.4%. This is the fourth consecutive year that Chengda Bio’s net profit has declined since its listing on the Science and Technology Innovation Board in 2021. Although the company has dominated the domestic human rabies vaccine market for 16 consecutive years since 2008, as more challengers have entered the market, its market share has fallen from more than 70% at its peak to less than 40% in 2024. In recent years, Chengda Bio has tried to find a second growth line, but with little success. The Japanese encephalitis inactivated vaccine launched in 2008 has accounted for less than 10% of the company’s revenue so far, and ...
- Source: drugdu
- 198
- March 4, 2025
Profits soared 8829%! Sinocell’s magnificent comeback

Recently, Sinocell released its 2024 performance report, and the results are quite impressive. In 2024, Sinocell’s total operating revenue was 2.513 billion yuan, a year-on-year increase of 33.13%. Operating profit reached 568 million yuan, a year-on-year increase of 8829.33%, and the net profit attributable to the parent company’s owners was 112 million yuan, successfully turning losses into profits. In addition, the non-net profit also reached 474 million yuan, also turning losses into profits. 1 2 billion single product Sinocell is a leading innovative biopharmaceutical R&D and industrial development company founded by Dr. Xie Liangzhi, an internationally renowned biopharmaceutical expert. The company was listed on the Science and Technology Innovation Board in 2020, and launched its first listed product, recombinant human coagulation factor VIII for injection (Anjiayin) in 2021. In 2024, the company finally turned losses into profits. According to the announcement of Sinocell, the company’s total operating income in 2024 ...
- Source: drugdu
- 262
- March 4, 2025
CanSino Biologics’ 2024 loss narrowed by more than 70%, and the launch of the innovative quadruple vaccine boosted revenue

“Science and Technology Innovation Board Daily” reported on February 28 (special correspondent Gao Qing) that vaccine company CanSino Biologics (688185.SH) released its 2024 performance report. The announcement showed that CanSino Biologics achieved revenue of 846 million yuan in 2024, an increase of 137.01% year-on-year, and a net profit loss of 379 million yuan, a year-on-year reduction of 74.45%. The net profit loss after deducting non-recurring items was 441 million yuan, a year-on-year decrease of 72.61%. Due to a sharp decline in revenue related to the new crown vaccine, CanSino Biologics’ 2023 performance loss once exceeded 1.4 billion yuan. Judging from the latest performance, the company has come out of that low period. In the announcement, CanSino mentioned that the company’s revenue increased significantly compared with the same period last year. The main reason is that its vaccine product Manhaixin®, as the only quadrivalent meningococcal conjugate vaccine in the Chinese market, ...
- Source: drugdu
- 303
- March 3, 2025
The 2025 National Drug Inspection Work Conference was held

The reporter learned from the National Drug Administration that on February 25, the 2025 National Drug Inspection Work Conference was held in Nanchang. The meeting summarized the results of the 2024 drug inspection work, deeply analyzed the current situation, exchanged inspection work experience, and deployed key tasks for 2025. The meeting required that drug regulatory departments and drug testing institutions at all levels strictly implement the “four strictest” requirements, follow the working ideas of “being political, strengthening supervision, ensuring safety, promoting development, and benefiting people’s livelihood”, and jointly carry out drug inspection work, and play an important role in discovering and eliminating risks and hidden dangers, continuously improving drug quality, and ensuring the safety of public drug use. It is necessary to strengthen political guidance, strictly implement responsibilities, firmly establish risk awareness, adhere to problem orientation, strengthen capacity building, improve work mechanisms, coordinate annual drug inspection work, and effectively improve ...
- Source: drugdu
- 278
- March 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.